Sindrome metabolica: studi per un possibile trattamento con melatonina.



La sindrome metabolica (SM) è rappresentata da una serie di fattori di rischio per le malattie cardiovascolari, tra cui l'obesità, l'ipertensione, l'iperinsulinemia, intolleranza al glucosio e la dislipidemia; associati ad un basso grado di infiammazione del tessuto adiposo bianco. Lo squilibrio tra segnali infiammatori e anti-infiammatori è cruciale nell'invecchiamento. L'integrazione con melatonina può contrastare questi fenomeni in quanto è noto che i livelli di melatonina diminuiscono nel corso della senescenza e sono fortemente ridotti nelle malattie legate all'insulinoresistenza.

Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies.

Neuroendocrinology. 2016 May 11;

Authors: Cardinali DP, Hardeland R

Abstract
The metabolic syndrome (MS) is a collection of risk factors for cardiovascular disease, including obesity, hypertension, hyperinsulinemia, glucose intolerance and dyslipidemia. MS is associated with low-grade inflammation of the white adipose tissue, which can subsequently lead to insulin resistance, impaired glucose tolerance and diabetes. Adipocytes secrete proinflammatory cytokines as well as leptin and trigger a vicious circle which leads to additional weight gain largely as fat. The imbalance between inflammatory and anti-inflammatory signals is crucial to aging. Healthy aging can benefit from melatonin, a compound known to possess direct and indirect antioxidant properties, to have a significant protective effect on mitochondrial function, to enhance circadian rhythm amplitudes, to modulate the immune system and to exhibit neuroprotective actions. Melatonin levels decrease in the course of senescence and are more strongly reduced in diseases related to insulin resistance. This short review article analyzes the multiple protective actions of melatonin that are relevant to the attenuation of inflammatory responses and progression of inflammaging and how melatonin is effective to curtail MS in animal models of hyperadiposity. The clinical data supporting the possible therapeutical use of melatonin in human MS are also reviewed. Since attention has been focused on the development of potent melatonin analogs with prolonged effects (ramelteon, agomelatine, tasimelteon, piromelatine) and in clinical trials these analogs were administered in doses considerably higher than those usually employed for melatonin, clinical trials on melatonin in the range of 50-100 mg/day are needed to further assess its therapeutic value in MS.

PMID: 27165273 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/27165273?dopt=Abstract

Share |


Melatonina.it l'unico portale interamente dedicato alla melatonina in italia
Versione multilingue del sito Key Melatonin

Sito conforme al prov. n. 229 - 08/05/2014 Codice Privacy in quanto utilizza esclusivamente cookies tecnici


Clavis Chitosano Vegetale
Integratore alimentare a base di CHITOSANO VEGETALE ( KiOnutrime-Cs ).
Chitosano Vegetale

Clavis Harmoniae
Clavis Harmoniae

Key Alghe
Linea di integratori alimentari a base di alghe
Key Alghe